AVALON GLOBOCARE CORP
AVALON GLOBOCARE CORP
Share · US05344R1041 · AVCO (XNAS)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,00 % -70,46 %

Company Profile for AVALON GLOBOCARE CORP Share

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Company Data

Name AVALON GLOBOCARE CORP
Company Avalon GloboCare Corp.
Symbol AVCO
Website https://www.avalon-globocare.com
Primary Exchange XNAS NASDAQ
ISIN US05344R1041
Asset Class Share
Sector Real Estate
Industry Real Estate - Services
CEO Dr. David K. Jin
Country United States of America
Currency USD
Employees 0,0 T
Address 4400 US Highway 9 Ste 3100, 07728 Freehold
IPO Date 2016-02-22

Stock Splits

Date Split
05.01.2023 1:10

Ticker Symbols

Name Symbol
NASDAQ AVCO

More Shares

Investors who AVALON GLOBOCARE CORP hold also have the following shares in their portfolio:
SPDR BLOOMBERG BARCLAYS CONVERTIBLE SECURITIES ETF
SPDR BLOOMBERG BARCLAYS CONVERTIBLE SECURITIES ETF ETF
USA 24/27
USA 24/27 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025